Insider Selling: Cardlytics Inc (NASDAQ:CDLX) Director Sells $2,216,329.06 in Stock

Cardlytics Inc (NASDAQ:CDLX) Director Bryce Youngren sold 64,786 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $34.21, for a total transaction of $2,216,329.06. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Bryce Youngren also recently made the following trade(s):

  • On Wednesday, August 14th, Bryce Youngren sold 174,695 shares of Cardlytics stock. The shares were sold at an average price of $33.70, for a total transaction of $5,887,221.50.
  • On Thursday, August 8th, Bryce Youngren sold 100,000 shares of Cardlytics stock. The shares were sold at an average price of $31.54, for a total transaction of $3,154,000.00.
  • On Thursday, July 25th, Bryce Youngren sold 88,030 shares of Cardlytics stock. The shares were sold at an average price of $29.12, for a total transaction of $2,563,433.60.
  • On Friday, July 19th, Bryce Youngren sold 34,274 shares of Cardlytics stock. The shares were sold at an average price of $27.92, for a total transaction of $956,930.08.
  • On Wednesday, July 17th, Bryce Youngren sold 68,727 shares of Cardlytics stock. The shares were sold at an average price of $27.66, for a total transaction of $1,900,988.82.
  • On Thursday, June 6th, Bryce Youngren sold 75,284 shares of Cardlytics stock. The shares were sold at an average price of $24.10, for a total transaction of $1,814,344.40.
  • On Tuesday, May 28th, Bryce Youngren sold 100,000 shares of Cardlytics stock. The shares were sold at an average price of $23.04, for a total transaction of $2,304,000.00.

Shares of Cardlytics stock opened at $32.41 on Friday. The company has a 50 day moving average of $29.75 and a 200-day moving average of $21.74. Cardlytics Inc has a 1-year low of $9.80 and a 1-year high of $34.64. The company has a current ratio of 2.01, a quick ratio of 2.01 and a debt-to-equity ratio of 0.79. The company has a market cap of $736.44 million, a PE ratio of -15.14 and a beta of 1.76.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.23. Cardlytics had a negative net margin of 19.60% and a negative return on equity of 66.01%. The company had revenue of $48.73 million during the quarter, compared to the consensus estimate of $43.77 million. During the same quarter in the prior year, the firm posted ($0.21) EPS. The firm’s quarterly revenue was up 37.0% on a year-over-year basis. Research analysts forecast that Cardlytics Inc will post -1.08 earnings per share for the current year.

A number of analysts have issued reports on CDLX shares. SunTrust Banks boosted their price objective on shares of Cardlytics from $25.00 to $35.00 and gave the company a “buy” rating in a report on Friday, August 9th. Zacks Investment Research downgraded shares of Cardlytics from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Raymond James boosted their price objective on shares of Cardlytics from $24.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, August 9th. JPMorgan Chase & Co. set a $43.00 price objective on shares of Cardlytics and gave the company a “buy” rating in a report on Friday, August 9th. Finally, KeyCorp boosted their price objective on shares of Cardlytics from $25.00 to $26.00 and gave the company an “overweight” rating in a report on Friday, May 10th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $33.29.

Institutional investors have recently modified their holdings of the company. FMR LLC raised its holdings in Cardlytics by 2.3% during the 1st quarter. FMR LLC now owns 3,284,572 shares of the company’s stock valued at $54,327,000 after buying an additional 72,847 shares during the last quarter. Frontier Capital Management Co. LLC lifted its position in shares of Cardlytics by 11.5% during the first quarter. Frontier Capital Management Co. LLC now owns 1,631,248 shares of the company’s stock worth $26,981,000 after purchasing an additional 168,471 shares during the last quarter. BlackRock Inc. lifted its position in shares of Cardlytics by 94.2% during the second quarter. BlackRock Inc. now owns 903,619 shares of the company’s stock worth $23,476,000 after purchasing an additional 438,215 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Cardlytics by 46.1% during the second quarter. Vanguard Group Inc. now owns 755,132 shares of the company’s stock valued at $19,618,000 after buying an additional 238,211 shares during the period. Finally, Grantham Mayo Van Otterloo & Co. LLC purchased a new position in shares of Cardlytics during the second quarter valued at $10,392,000. 75.09% of the stock is owned by institutional investors.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Featured Article: What Are Treasury Bonds?

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.